ReviewSeminars in hematology2020
Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis.
Review in Seminars in hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation.Nature medicine · 2023Trial
- Review
- Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface.Frontiers in microbiology · 2026Review
- Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.Frontiers in immunology · 2026Review
- Throwing the microbiome out with the bathwater.Blood advances · 2025Article
- Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.Molecular medicine (Cambridge, Mass.) · 2025Review
- A review on preparation and application of low-calorie structured lipids in food system.Food science and biotechnology · 2025Review
- Postbiotics as Adjuvant Therapy in Cancer Care.Nutrients · 2024Review
- Longitudinal dynamics of gut microbiota in the pathogenesis of acute graft-versus-host disease.Cancer medicine · 2023Article
- Mechanism of Acupuncture and Moxibustion on Promoting Mucosal Healing in Ulcerative Colitis.Chinese journal of integrative medicine · 2023Review
- Acute graft-versus-host disease.Nature reviews. Disease primers · 2023Review
- Effects of Exposure to Low Zearalenone Concentrations Close to the EU Recommended Value on Weaned Piglets' Colon.Toxins · 2023Article
- Bacterial Profile and Fatty Acid Composition of Anatolian Bee Bread Samples by Metataxonomic and Metabolomic Approach.Current microbiology · 2023Article
- Postbiotics in Human Health: A Narrative Review.Nutrients · 2023Review
- The emerging role of nutritional support in the supportive care of pediatric patients undergoing hematopoietic stem cell transplantation.Frontiers in nutrition · 2023Review
- Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients.Frontiers in nutrition · 2022Review
- A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.Oxidative medicine and cellular longevity · 2022Review
- Roles of the intestinal microbiota and microbial metabolites in acute GVHD.Experimental hematology & oncology · 2021Review
- Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation.Cancers · 2021Review
- Probiotics in Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acute Graft vs host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo HSCT), a potent form of cellular therapy that has the potential to cure malignant and benign hematological conditions. Gastrointestinal (GI) GVHD is the principal cause of nonrelapse mortality after allo HSCT. Allo HSCT alters the intestinal microbiota and recent research uncovered a microbiome-metabolome axis that can affect intestinal homeostasis and mitigate the severity of experimental GI GVHD. This axis can potentially be manipulated via dietary intervention or through probiotics or postbiotics or antibiotics in humans. In this review we summarize major findings of how microbial metabolites and particularly short chain fatty acids (SCFAs) could impact acute GI GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.